[Skip to Content]
[Skip to Content Landing]

Chemotherapy-Induced Hyperopic Surprise in a Woman With Multiple Myeloma

To identify the key insights or developments described in this article
1 Credit CME

A 64-year-old woman presented with worsening vision 4 weeks after a belantamab mafodotin, 2.5 mg/kg, infusion for multiple myeloma. Manifest refraction revealed a bilateral +5-diopter hyperopic shift. Slitlamp microscopy demonstrated peripheral corneal epithelial cystlike changes, previously described with belantamab mafodotin and other chemotherapeutic agents (Figure, A).15 Anterior-segment optical coherence tomography highlighted the cysts as small hyperreflective opacities (Figure, B). Pentacam (Oculus) anterior float maps showed a configuration similar to that seen after myopic laser ablation with central corneal flattening (Figure, B, left inset). Scheimpflug tomography pachymetry and corneal epithelial thickness maps (Figure, B, middle, right inset) revealed this was attributable to relative peripheral corneal epithelial thickening. The belantamab mafodotin infusions were discontinued, leading to normalization of her refractive error and resolution of her microcystic keratopathy within 4 and 6 weeks, respectively. Reduced dosage infusions (1.9 mg/kg) resumed with less dense microcyst recurrence. Rigid gas permeable lenses improved her vision to baseline.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Corresponding Author Address: Gerami D. Seitzman, MD, F. I. Proctor Foundation, University of California, San Francisco, 490 Illinois St, 2nd Floor, San Francisco, CA 94158 (gerami.seitzman@ucsf.edu).

Conflict of Interest Disclosures: Dr Seitzman reported receiving consultant fees from Dompe outside the submitted work. No other disclosures were reported.

Additional Contributions: We thank the patient for granting permission to publish this information.

References
1.
Corbelli  E , Miserocchi  E , Marchese  A ,  et al.  Ocular toxicity of mirvetuximab.   Cornea. 2019;38(2):229-232. doi:10.1097/ICO.0000000000001805PubMedGoogle ScholarCrossref
2.
Younes  A , Kim  S , Romaguera  J ,  et al.  Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.   J Clin Oncol. 2012;30(22):2776-2782. doi:10.1200/JCO.2011.39.4403PubMedGoogle ScholarCrossref
3.
Rousseau  A , Michot  J-M , Labetoulle  M .  Belantamab mafotodin-induced epithelial keratopathy masquerading myopic surgery.   Ophthalmology. 2020;127(12):1626. doi:10.1016/j.ophtha.2020.07.047PubMedGoogle ScholarCrossref
4.
Farooq  AV , Degli Esposti  S , Popat  R ,  et al.  Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study.   Ophthalmol Ther. 2020;9(4):889-911. doi:10.1007/s40123-020-00280-8PubMedGoogle ScholarCrossref
5.
Bausell  RB , Soleimani  A , Vinnett  A ,  et al.  Corneal changes after belantamab mafodotin in multiple myeloma patients.   Eye Contact Lens. 2021;47(6):362-365. doi:10.1097/ICL.0000000000000768PubMedGoogle ScholarCrossref
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close